Characterization of allergen-specific T cell subsets in allergy: With a goal for improvement of allergen-specific immunotherapy

Van Hemelen, D., 2016, [Groningen]: Rijksuniversiteit Groningen. 171 p.

Research output: ThesisThesis fully internal (DIV)

Copy link to clipboard


  • Title and contents

    Final publisher's version, 455 KB, PDF document

  • Chapter 1

    Final publisher's version, 516 KB, PDF document

  • Chapter 2

    Final publisher's version, 926 KB, PDF document

  • Chapter 3

    Final publisher's version, 1.13 MB, PDF document

  • Chapter 4

    Final publisher's version, 577 KB, PDF document

  • Chapter 5

    Final publisher's version, 1.02 MB, PDF document

  • Chapter 6

    Final publisher's version, 828 KB, PDF document

  • Chapter 7

    Final publisher's version, 0.99 MB, PDF document

  • Chapter 8

    Final publisher's version, 498 KB, PDF document

  • Chapter 9

    Final publisher's version, 415 KB, PDF document

  • Chapter 10

    Final publisher's version, 430 KB, PDF document

  • Chapter 11

    Final publisher's version, 428 KB, PDF document

  • Complete thesis

    Final publisher's version, 3.82 MB, PDF document

  • Propositions

    Final publisher's version, 503 KB, PDF document

  • Dries Van Hemelen
To improve the therapeutic efficacy of allergen-specific immunotherapy (SIT), the underlying mechanisms should be understood in full detail. Allergen-specific T cell modulation may play a crucial role, in particular regarding for the induction of long term therapeutic effect. In the first part of this thesis we compared different methods to target and phenotype these T cells. Here the method consisting of 8 day cultures using CFSE appeared superior in the power to detect differences between allergic and non-allergic individuals. Therefore this methodology was used for the analysis of T cells in 2 different clinical trials in the second part of this Thesis. In the first trial the differences between Wasp-venom allergic patients with and without mastocytosis were studied during VIT. After 6 weeks of treatment we only observed a reduction in the allergy causing Th2 cells within the wasp-venom allergic patients not suffering from mastocytosis. The difference in this T cell modulation between the two treatment groups might explain the lack of long term symptom suppression seen in mastocytosis patients suffering from wasp-venom allergy. In a second clinical trial (VITAL), the adjuvant effects of Vitamin D3 was studied on grass-pollen SIT. Unfortunately the grass-pollen SIT did not result in a clinical improvement, precluding a definite conclusion on the potential adjuvant Vitamin D3.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Award date29-Feb-2016
Place of Publication[Groningen]
Print ISBNs978-94-6299-298-6
Publication statusPublished - 2016

Download statistics

No data available

ID: 28607301